Education
About Us
Working with TipRanks
Follow Us
ImmunoPrecise Antibodies (IPA)
NASDAQ:IPA
Top Page
ImmunoPrecise Antibodies
(NASDAQ:IPA)
51Neutral
Positive Factors
Financial Health
The company completed an equity raise and converted the remaining balance of its debentures, ending the quarter with $12.9 million in cash and no long-term debt.
Insider Confidence
Insiders recently completed 763,000 in open market share purchases, indicating confidence in the company's future.
Strategic Partnerships
A new $8-$10 million co-development partnership with a large biotech firm and strategic agreements for generative AI in drug development highlight growth potential.
Negative Factors
Financial Performance
The company reported FY3Q25 revenues of C$6.2M and a net loss of C$0.66 per diluted share, compared to the consensus estimated revenues of C$7.0M and a net loss of C$0.08 per share.
Market and Regulatory Risks
IPA shares have declined this year with a dip in the overall market and uncertainties related to potential drug tariffs and government R&D spending.
ImmunoPrecise Antibodies (IPA) vs. S&P 500 (SPY)
Market Cap
$20.04M
Dividend YieldN/A
Average Volume (3M)1.66M
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth-0.71%
EPS Growth-169.29%
CountryUS
Employees72
SectorHealthcare
Sector Strength66
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.13
Shares Outstanding45,765,118
10 Day Avg. Volume489,974
30 Day Avg. Volume1,661,414
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.79
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.00Price Target Upside809.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
ImmunoPrecise Antibodies Business Overview & Revenue Model
Company DescriptionImmunoPrecise Antibodies (IPA) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. Operating within the life sciences sector, IPA provides a broad range of services, including custom antibody generation, characterization, engineering, and production. The company's core products and services focus on antibody discovery and development solutions tailored to meet the needs of pharmaceutical and biotechnology companies globally.
How the Company Makes MoneyImmunoPrecise Antibodies makes money primarily through service contracts with pharmaceutical and biotechnology companies. Its revenue model is based on providing comprehensive antibody discovery and development services, which include custom antibody generation, screening, and optimization. These services are offered on a fee-for-service basis, allowing clients to access IPA's proprietary technologies and expertise without significant upfront investment. Additionally, IPA may enter into collaborative agreements or partnerships with other companies, which can include milestone payments, licensing fees, and royalties on successful therapeutic antibodies developed through their platforms. The company's earnings are also supported by its ability to offer tailored solutions across various stages of drug discovery, leveraging its advanced technologies to meet specific client needs.
ImmunoPrecise Antibodies Financial Statement Overview
Summary
ImmunoPrecise Antibodies faces significant financial challenges, with declining revenues, persistent losses, and negative cash flow metrics. The company's high leverage and low equity returns are concerning, indicating the need for strategic adjustments to improve financial health and operational efficiency.Income Statement
The company has experienced a decline in revenue growth, with a negative trend in net income over the TTM period. Gross profit margin stands at an acceptable level, but the net profit margin and EBIT margin are negative, indicating operational challenges. The EBITDA margin is also negative, highlighting further profitability concerns.45
Neutral
Balance Sheet
The debt-to-equity ratio has increased, suggesting higher leverage and potential financial risk. However, the company maintains a reasonable equity ratio, indicating a fair level of stability. Return on equity is negative due to persistent net losses, which is concerning for investors.50
Neutral
Cash Flow
Free cash flow has declined significantly, reflecting operational and capital expenditure pressures. The operating cash flow to net income ratio is negative, indicating cash flow inefficiencies. The free cash flow to net income ratio is also negative, highlighting challenges in generating cash from operations.40
Negative
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 24.07M | 24.52M | 20.66M | 19.36M | 17.91M | 14.06M | Gross Profit |
| 12.10M | 12.05M | 11.56M | 10.98M | 11.54M | 8.03M | EBIT |
| -13.35M | -13.76M | -26.09M | -15.78M | -6.65M | -4.09M | EBITDA |
| -9.23M | -22.95M | -21.04M | -11.99M | -1.42M | -449.00K | Net Income Common Stockholders |
| -27.54M | -27.18M | -26.56M | -16.71M | -7.34M | -4.95M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 6.20M | 3.46M | 8.28M | 29.96M | 41.76M | 2.61M | Total Assets |
| 78.69M | 59.99M | 77.81M | 93.49M | 66.96M | 27.26M | Total Debt |
| 14.39M | 13.68M | 7.27M | 2.55M | 3.46M | 4.51M | Net Debt |
| 8.19M | 10.22M | -1.01M | -27.42M | -38.30M | 1.90M | Total Liabilities |
| 28.87M | 26.07M | 20.01M | 18.21M | 10.04M | 12.18M | Stockholders Equity |
| 49.82M | 33.92M | 57.80M | 75.28M | 56.92M | 15.09M |
| Cash Flow | Free Cash Flow | ||||
| -8.56M | -5.64M | -21.33M | -11.18M | -2.03M | -1.97M | Operating Cash Flow |
| -7.17M | -4.25M | -19.83M | -9.92M | -600.00K | -1.39M | Investing Cash Flow |
| -1.38M | -1.56M | -1.97M | -5.21M | -2.46M | -1.58M | Financing Cash Flow |
| 6.50M | 1.02M | -621.00K | 2.88M | 43.38M | 174.70K |
ImmunoPrecise Antibodies Technical Analysis
Positive
0.44
Price Trends
0.41
Positive
0.43
Positive
0.56
Negative
Market Momentum
<0.01
Negative
55.16
Neutral
65.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPA, the sentiment is Positive. The current price of 0.44 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.41, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.16 is Neutral, neither overbought nor oversold. The STOCH value of 65.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IPA.
ImmunoPrecise Antibodies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $20.04M | ― | -121.65% | ― | -0.71% | -169.29% | |
51 Neutral | $5.19B | 3.12 | -41.08% | 2.95% | 17.98% | 2.02% | |
45 Neutral | $20.51M | ― | -33.88% | ― | 44.50% | 49.72% | |
43 Neutral | $19.44M | ― | -51.43% | ― | ― | 7.07% | |
39 Underperform | $20.51M | ― | -75.07% | ― | ― | 42.39% |
* Healthcare Sector Average
Performance Comparison
IPA
ImmunoPrecise Antibodies
0.44
-0.81
-64.80%
LSTA
Lisata Therapeutics
2.26
-0.41
-15.36%
OVID
Ovid Therapeutics
0.29
-2.86
-90.79%
PASG
Passage Bio
0.33
-0.81
-71.05%
ImmunoPrecise Antibodies Earnings Call Summary
Earnings Call Date: Mar 28, 2025 | % Change Since: 0.00% | Next Earnings Date: Jul 24, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements, including strategic partnerships, financial strengthening, and substantial growth in AI and biologics, overshadowing concerns about increased operating expenses and broader industry challenges.Highlights
Strategic Partnership
Secured a strategic partnership valued at US$8 million to US$10 million with a leading biotech company, leveraging proprietary B-cell select technology and AI-driven capabilities.
Relocation and Expansion
Relocated corporate headquarters to Austin, Texas, expanding US footprint in a thriving AI and biotech ecosystem.
Financial Strength
Strengthened financial position with US$8.8 million equity raise and full conversion of Yorkville debenture, making the company debt-free.
AI and Biologics Growth
BioStrand achieved a 131.8% year-over-year revenue increase with an average gross profit margin of 97% year-to-date.
Partnerships and Collaborations
Collaborations with key technology partners like Vultr and AMD, enhancing lab-in-a-loop drug discovery capabilities.
Lowlights
Operating Expenses Increase
Operating expenses for the quarter totaled $27.8 million, driven largely by a non-cash impairment charge of $21.2 million related to BioStrand's intangible assets.
Biotech Industry Challenges
The biotech industry has faced significant capital constraints, with 41 companies filing for bankruptcy in 2023.
Company Guidance
In the third quarter of fiscal year 2025, ImmunoPrecise Antibodies (IPA) reported strong financial and operational progress, as detailed in their earnings call. The company secured a significant strategic partnership valued between $8 million to $10 million, leveraging its proprietary B-cell select technology and AI capabilities. The relocation of IPA's headquarters to Austin, Texas, aims to enhance its presence in the U.S. biotech and AI ecosystem. Financially, IPA raised $8.8 million in equity, completed the full conversion of the Yorkville debenture, and ended the quarter with CAD12.9 million in cash, significantly reducing financial risk. The company reported a consistent revenue of $6.2 million, with BioStrand achieving a remarkable 131.8% year-over-year revenue increase and an average gross profit margin of 97% year-to-date. IPA's strategic initiatives include a potential divestiture of its EU lab to enhance operational efficiency and focus. The company anticipates that its AI-driven platforms will continue to scale, enhancing profitability and positioning IPA for sustainable long-term growth.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.